BR112017015567A2 - proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica - Google Patents

proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica

Info

Publication number
BR112017015567A2
BR112017015567A2 BR112017015567A BR112017015567A BR112017015567A2 BR 112017015567 A2 BR112017015567 A2 BR 112017015567A2 BR 112017015567 A BR112017015567 A BR 112017015567A BR 112017015567 A BR112017015567 A BR 112017015567A BR 112017015567 A2 BR112017015567 A2 BR 112017015567A2
Authority
BR
Brazil
Prior art keywords
cytomegalovirus
complex
protein
nucleic acid
host cell
Prior art date
Application number
BR112017015567A
Other languages
English (en)
Portuguese (pt)
Inventor
Carfi Andrea
Ciferri Claudio
Xing Yi
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112017015567A2 publication Critical patent/BR112017015567A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017015567A 2015-01-22 2016-01-22 proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica BR112017015567A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15152221.6A EP3048114A1 (en) 2015-01-22 2015-01-22 Cytomegalovirus antigens and uses thereof
PCT/IB2016/050335 WO2016116904A1 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof

Publications (1)

Publication Number Publication Date
BR112017015567A2 true BR112017015567A2 (pt) 2018-03-13

Family

ID=52434568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015567A BR112017015567A2 (pt) 2015-01-22 2016-01-22 proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica

Country Status (24)

Country Link
US (2) US10167321B2 (enExample)
EP (3) EP3048114A1 (enExample)
JP (1) JP6717836B2 (enExample)
KR (1) KR20170100039A (enExample)
CN (1) CN107531761B (enExample)
AU (2) AU2016210548B2 (enExample)
BE (1) BE1023087B1 (enExample)
BR (1) BR112017015567A2 (enExample)
CA (1) CA2974041C (enExample)
DK (1) DK3247722T5 (enExample)
EA (1) EA038250B1 (enExample)
ES (1) ES2937959T3 (enExample)
FI (1) FI3247722T3 (enExample)
HR (1) HRP20230177T1 (enExample)
HU (1) HUE061175T2 (enExample)
IL (1) IL253366B (enExample)
LT (1) LT3247722T (enExample)
MX (1) MX382518B (enExample)
PL (1) PL3247722T3 (enExample)
PT (1) PT3247722T (enExample)
SG (1) SG11201705740UA (enExample)
SI (1) SI3247722T1 (enExample)
WO (1) WO2016116904A1 (enExample)
ZA (1) ZA201704912B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802741T4 (tr) * 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN113528466B (zh) 2014-07-16 2024-12-24 俄勒冈健康与科学大学 包含外源抗原的人巨细胞病毒
SG11201706454VA (en) 2015-02-10 2017-09-28 Univ Oregon Health & Science Methods and compositions useful in generating non canonical cd8+ t cell responses
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
CN108474003A (zh) 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
WO2017152146A2 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
WO2018067580A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
BR112019007982A2 (pt) 2016-10-18 2019-07-02 Univ Oregon Health & Science vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
US11773144B2 (en) 2017-10-02 2023-10-03 Duke University Mosaic HIV-1 envelopes to induce ADCC responses
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CN109627330A (zh) * 2018-12-18 2019-04-16 马鞍山史记动物健康管理有限公司 一种猪伪狂犬病毒高效价阳性血清制备方法
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN118580343B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
CA2654563A1 (en) 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP2352759B1 (en) * 2008-07-16 2017-11-01 Institute for Research in Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
ES2649896T3 (es) 2010-07-06 2018-01-16 Glaxosmithkline Biologicals Sa Emulsiones catiónicas de aceite en agua
CA2814386C (en) 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
MX378747B (es) 2012-07-06 2025-03-10 Glaxosmithkline Biologicals S A Star Complejos de proteínas de citomegalovirus.
US20150359879A1 (en) * 2012-10-30 2015-12-17 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
MX373329B (es) 2013-12-20 2020-05-21 Novartis Ag Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
LT3083676T (lt) 2013-12-20 2019-11-25 Novartis Ag Naujos eukariotinės ląstelės, ir dominančio polipeptido rekombinantinės raiškos būdai
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof

Also Published As

Publication number Publication date
EA038250B1 (ru) 2021-07-29
SG11201705740UA (en) 2017-08-30
DK3247722T5 (da) 2024-10-07
EP3247722A1 (en) 2017-11-29
IL253366B (en) 2022-03-01
CN107531761B (zh) 2022-01-14
AU2018226521A1 (en) 2018-09-27
EP3247722B1 (en) 2022-11-30
JP6717836B2 (ja) 2020-07-08
AU2016210548B2 (en) 2018-11-08
CA2974041A1 (en) 2016-07-28
CN107531761A (zh) 2018-01-02
ES2937959T3 (es) 2023-04-03
AU2018226521B2 (en) 2019-10-31
WO2016116904A1 (en) 2016-07-28
LT3247722T (lt) 2023-02-10
FI3247722T3 (fi) 2023-03-17
PT3247722T (pt) 2023-01-31
US20190276498A1 (en) 2019-09-12
BE1023087A1 (fr) 2016-11-18
SI3247722T1 (sl) 2023-04-28
EP4180056A1 (en) 2023-05-17
BE1023087B1 (fr) 2016-11-18
HUE061175T2 (hu) 2023-05-28
IL253366A0 (en) 2017-09-28
AU2016210548A1 (en) 2017-08-10
CA2974041C (en) 2023-04-04
DK3247722T3 (da) 2023-01-30
MX382518B (es) 2025-03-13
JP2018504117A (ja) 2018-02-15
ZA201704912B (en) 2018-12-19
KR20170100039A (ko) 2017-09-01
US10167321B2 (en) 2019-01-01
HRP20230177T1 (hr) 2023-04-14
MX2017009538A (es) 2017-11-02
US20170369532A1 (en) 2017-12-28
PL3247722T3 (pl) 2023-03-20
EP3048114A1 (en) 2016-07-27
EA201791562A1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
PH12019500596B1 (en) Recombinant binding proteins and their use
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
MX2023001119A (es) Variantes de enzimas y polinucleotidos que las codifican.
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
MX385926B (es) Proteínas de fusión de citoquinas.
BR112017008976A2 (pt) ?composição, métodos de aumento da viscosidade de composições aquosas, de tratamento de material, de produção de dextrano e reação enzimática?
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
AU2016229053A8 (en) Fusion protein comprising a ligand binding domain of VEGF and PDGF
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112015003724A2 (pt) polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína.
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
BR112015021960A2 (pt) Células hospedeiras e métodos de uso
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
BR112017000710A2 (pt) polipeptídeo isolado, polipeptídeo modificado de revestimento final isolado, composição de matéria, polipeptídeo de fusão isolado, composição farmacêutica, método de tratamento de uma doença inflamatória, uso do polipeptídeo isolado, polinucleotídeo isolado, estrutura de ácido nucleico, e método de determinação da potência de um lote do polipeptídeo isolado
AR106716A1 (es) Anticuerpos anti-factor d y conjugados
BR112016027897A2 (pt) polipeptídio multimérico, ácido nucleico, vetor de expressão recombinante, célula hospedeira geneticamente modificada, composição, método, e, método de tratamento de uma infecção num indivíduo
BR112014027168A2 (pt) proteína, polipeptídeo. ácido nucleico, vetor de expressão, microrganismo, mistura e uso da proteína
TW201612317A (en) Gene, composition and method for improving lignocelluloses hydrolyzation

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.